Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

References

• CDC fact sheet http://www.cdc.gov/diabetes/pubs/factsheet07.htmAccessed April 2, 2009
   Google Scholar
• The Diabetes Control and Complications Research GroupThe effect of intensive diabetes treatment on the development and progression of long term complications in insulin dependent diabetes mellitusN Engl J Med19933299779868366922
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in subjects with type 2 diabetes mellitus. (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• KoroCEBowlinSJBourgeoisNFedderDOGlycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: A preliminary reportDiabetes Care200427172014693960
   PubMed Web of Science ®Google Scholar
• ElrickHStimmlerLHladCJAraiYPlasma insulin responses to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• DruckerDEnhancing incretin action for the treatment of type 2 diabetesDiab Care20032629292940
   PubMed Web of Science ®Google Scholar
• ElahiDMcAloon-DykeMFukagawaNKMeneillyGSSclaterALMinakerKLThe insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like polypeptide 1 (7–37) in normal and diabetic subjectsRegul Pept19945163748036284
   PubMed Web of Science ®Google Scholar
• TsengCCZhangXYWolfeMMEffect of GIP and GLP-11 antagonists on insulin release in the ratAm J Physiol1999276E1049E105410362617
   PubMed Web of Science ®Google Scholar
• JonesIROwensDRVoraJLuzioSDHayesTMA supplementary infusion of glucose – dependent insulinotrpic olypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitusDiabetes Res Clin Pract198972632692693029
   PubMed Web of Science ®Google Scholar
• TsengCCBoylanMOJarboeLAUsdinTBWolfeMMChronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in ratsAm J Physiol1996270E661E6668928774
   PubMed Web of Science ®Google Scholar
• BellGISanchez-PescadorRLaybournPJNajarianRCExon duplication and divergence in the human preproglucagon geneNature19833043683716877358
   PubMed Web of Science ®Google Scholar
• HermannCGokeRRichterGFehmannHCArnoldRGokeBGlucagon-like peptide 1 and glucose dependent insulin releasing polypeptide plasma levels in response to nutrientsDigestion1995561171267750665
   PubMed Web of Science ®Google Scholar
• ElliotRMMorganLMTredgerJADeaconSWrightJMarksVGlucagon-like peptide 17–36 amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24 hour secretion patternsJ Endocrinol19931381591667852887
   PubMed Web of Science ®Google Scholar
• VahlTPPatyBWFullerBDPrigeonRLD’AlessioDAEffects of GLP-1-1-(7–36)NH(2), GLP-1–1-(7–37), and GLP-1–1-(9–36)NH(2) on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humansJ Clin Endocrinol Metab2003881772177912679472
   PubMed Web of Science ®Google Scholar
• MatsuyamaTKomatsuRNambaMWatanabeNItohHTaruiSGlucagon-like peptide 1 (7–36 amide): a potent glucagonostatic and insulinotropic hormoneDiabetes Res Cln Pract19885281284
   PubMed Web of Science ®Google Scholar
• TurtonMDO’SheaDGunnIBeakSAEdwardsCMBMeeranKA role for glucagon-like peptide-1 in the central regulation of feedingNature199637969728538742
   PubMed Web of Science ®Google Scholar
• LugariRDeiCAUgolottiDFinardiLBarilliAOgnibeneCEvidence for early impairment of glucagon-like peptide 1 induced insulin secretion in human type 2 (non-insulin dependent) diabetesHorm Metab Res20023415015411972305
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTDeaconCFMadsbadSHolstJJReduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patientsDiabetes20015060961311246881
   PubMed Web of Science ®Google Scholar
• RaskEOlssonTSoderbergSImpaired incretin response after a mixed meal is associated with insulin resistance in non-diabetic menDiabetes Care2001241640164511522713
   PubMed Web of Science ®Google Scholar
• MentleinRGallwitzBSchmidtWEDipeptidyl-peptidase 4 hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7–36) amide, peptide histidine methionine and is responsible for their degradation in human serumEur J Biochem19932148298358100523
   PubMedGoogle Scholar
• VilsbollTAgersoHKrarupTHolstJJSimilar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjectsJ Clin Endocrinol Metab20038822022412519856
   PubMed Web of Science ®Google Scholar
• EngJKleinmanWASinghLSinghGRaufmanJPIsolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venomJ Biol Chem1992267740274051313797
   PubMed Web of Science ®Google Scholar
• ChenYEDruckerDJTissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizardJ Biol Chem1997272410841159020121
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and CDER Drug and Biologic Approvals for Calendar Year 2005 www.fda.gov/cder/rdmt/InternetNDA05.htmAccessed April14, 2009
   Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBarronADthe Exenatide-113 Clinical Study GroupEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care2004272628263515504997
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJKimDDFinemanMSBarronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patient with type 2 diabetesDiabetes Care2005281092110015855572
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJZhuangDKimDDFinemanMSEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care2005281083109215855571
   PubMed Web of Science ®Google Scholar
• RatnerREMaggsDNielsenLLStonehouseAHPoonTZhangBLong-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitusDiabetes Obes Metab2006841942816776749
   PubMed Web of Science ®Google Scholar
• BlondeLKleinEJHanJZhangBMacSMPoonTHInterim analysis of the effects of exenatide treatment on A1C, weight, and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes Obes Metab2006843644716776751
   PubMed Web of Science ®Google Scholar
• RiddleMCHenryRRPoonTHZhangBMacSMHolcombeJHExenatide elicts sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonulureas with or without metforminDiabetes Metab Res Rev20062248349116634116
   PubMed Web of Science ®Google Scholar
• BuseJBKlonoffDCNielsenLLGuanXBowlusCLHolcombeJHMetabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialsClinical Therap20072913915317379054
   PubMed Web of Science ®Google Scholar
• KimDMacConellLZhuangDKotharePATrautmannMFinemanMEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care2007301487149317353504
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKKendallDMTrautmannMZhuangDDURATION-1 Study GroupExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority studyLancet20083721240125018782641
   PubMed Web of Science ®Google Scholar
• RichardsonKMedscape diabetes and endocrinology. incretin-based therapies in type 2 diabetes: An expert interview with John B. Buse, MD, PhD, CDE200881 http://www.medscape.com/viewarticle/537094Accessed March 6, 2009
   Google Scholar
• HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRGGWAA Study GroupExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med200514355956916230722
   PubMed Web of Science ®Google Scholar
• DavisSNJohnsDMaggsDXuHNorthrupJHBrodowsRGExploring the substitution of exenatide for insulin in patient with type 2 diabetes treated with insulin in combination with oral antidiabetes agentsDiabetes Care2007302767277217595353
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDBrodowsRKendallDMRobertsATolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, cross-over noninferiority trialClin Ther2007292333234818158075
   PubMed Web of Science ®Google Scholar
• NauckMADuranSKimDJohnsDNorthrupJFestaAA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and meformin: a non-inferiority studyDiabetologia20075025926717160407
   PubMed Web of Science ®Google Scholar
• BergenstalRLewinABaileyTChangDBylvinTRobertsNovoLog Mix vs Exenatide Study GroupEfficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylureaCurr Med Res Opin200925657519210140
   PubMed Web of Science ®Google Scholar
• GlassLDQUYLenoxSKimDGatesJRBrodowsREffects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysisCurr Med Res Opin20082463964418218179
   PubMed Web of Science ®Google Scholar
• SchwartzSLRatnerREKimDDQuYFechnerLLLenoxSMEffect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week studyClin Ther20083085886718555933
   PubMed Web of Science ®Google Scholar
• ZinmanBHoogwerfBJDuran GarciaSMiltonDRGiaconiaJMKimDDThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med200714647748517404349
   PubMed Web of Science ®Google Scholar
• DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagons secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin2008242943295218786299
   PubMed Web of Science ®Google Scholar
• FehseFTrautmannMHolstJJHalsethAENanayakkaraNNielsenLLExenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetesJ Clin Endo Metab20052923332348
   Google Scholar
• BunckMCDiamantMCornerAEliassonBMalloyJLShaginianRMOne-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: A randomized, controlled trialDiab Care2009 [Epub ahead of print] PMID 19196887
   Web of Science ®Google Scholar
• MariANielsenLLNanayakkaraNDeFronzoRAFerranniniEHalsethAMathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylureaHorm Metab Res20063883884417163361
   PubMed Web of Science ®Google Scholar
• BlaséEDengWWalshBFinemanMRhodesCIntranasal administration of exenatide in patients with type 2 diabetes: pharmacokinetics, pharmacodynamics, safety, and tolerability American Diabetes Association, 68th Scientific Sessions2008 abstract 195-OR
   Google Scholar
• BunckMCCornerADiamantMEliassonBMalloyJLShaginianRMExenatide improves postprandial hyperglycemia and dyslipidemia in metformin treated patients with type 2 diabetes American Diabetes Association. 68th Scientific Sessions2008 abstract 109-OR
   Google Scholar
• BulchandaniKNachnaniJSEatonCHamburgMExenatide leads to reduction in liver enzymes in diabetics independent of weight loss. American Association of Clinical Endocrinologists Annual Meeting2008 abstract 240
   Google Scholar